World Sleep Industry ENCYCLOPEDIA

Mirtazapine

2.1.1

Drug identity, approved use, and the source of sedation

Mirtazapine is a tetracyclic antidepressant. The current United States label for oral tablets approves it for major depressive disorder in adults, not for insomnia. Its antidepressant mechanism is not fully established but may involve blockade of central presynaptic alpha-2 adrenergic receptors, enhancement of noradrenergic and serotonergic activity, and antagonism at 5-HT2 and 5-HT3 receptors. Strong histamine H1 antagonism helps explain prominent somnolence, while peripheral alpha-1 activity helps explain some orthostatic hypotension.

Sleepiness is a pharmacologic effect and a common adverse reaction; it is not automatically restorative sleep or improved all-day function. Lower-dose use for insomnia is off-label. When mirtazapine is used for depression accompanied by insomnia, mood response and same-night sedation should still be evaluated separately. It should not be treated as an ordinary sleep aid without metabolic, psychiatric, or discontinuation risks. The popular claim that a lower dose is always more sedating is not a reliable personal conversion rule, and it should not be used to reverse or adjust a prescription without the prescriber.

Insomnia trial evidence, time limits, and cause assessment

A 2025 primary-care randomized trial enrolled 80 adults with sleep-maintenance insomnia whose nonpharmacologic treatment had been insufficient. Mirtazapine produced better insomnia-severity results than placebo at six weeks, but the difference was no longer significant from week twelve onward, and the findings did not support routine use for several months. A separate 2025 trial enrolled 60 adults aged at least 65 years with chronic insomnia. At four weeks, insomnia severity, subjective wake after sleep onset, total sleep time, and sleep efficiency improved, but more mirtazapine recipients discontinued because of adverse effects. Both trials were small and short and cannot establish long-term net benefit.

These results support the possibility of short-term benefit in selected patients, not applicability to every age, insomnia phenotype, or comorbidity. Chronic insomnia still calls for cognitive behavioral therapy for insomnia as first-line or parallel care and assessment of sleep opportunity, schedule, sleep apnea, restless legs, pain, nocturia, substance use, mania, and other medicines. More sleep at night does not establish success if it comes with daytime slowing, continuing appetite or weight gain, falls, or worsening mood. Benefit and harm need early and continuing reassessment.

Timing, long half-life, and formulation boundaries

Mirtazapine must be used according to the exact product and prescription. The current United States antidepressant-tablet label calls for once-daily administration, usually in the evening before sleep; food has little effect on the rate or extent of absorption. Conventional swallowed tablets and orally disintegrating tablets may differ in excipients, handling, and whether they can be divided, so the instructions for the product in hand control. A patient should not redose after waking during the night, double a missed or uncertain dose, change the dose according to one night's drowsiness, or repurpose another person's antidepressant prescription for sleep.

Peak concentration occurs in about two hours, the elimination half-life is roughly 20 to 40 hours, and steady state with accumulation is reached in about five days. Sedating effects may therefore extend into the next day. Mirtazapine is metabolized through pathways involving CYP1A2, CYP2D6, and CYP3A and is eliminated mainly in urine. Clearance may fall in older people and in moderate-to-severe renal or hepatic impairment. Strong CYP3A inhibitors can raise exposure, while strong inducers such as carbamazepine, phenytoin, or rifampin can lower it. Adjustments belong with a prescriber who can review the complete medication list and clinical response.

Somnolence, metabolic weight effects, and sleep-breathing risk

Somnolence, increased appetite, weight gain, dry mouth, constipation, and dizziness are important common adverse effects. After initiation or a regimen change, the patient should not drive, cycle, work at height, operate machinery, or undertake a high-alertness task until alertness, reaction, and coordination are known to be unaffected. Alcohol, benzodiazepines, and other central nervous system depressants add to cognitive and motor impairment. Older adults are more vulnerable to over-sedation, confusion, hyponatremia, and falls; nighttime rising should be slow and the route well lit.

Appetite and weight should be assessed against baseline and over time, with waist, lipids, and other metabolic risks considered when relevant. Mirtazapine can raise cholesterol and triglycerides. It is not a treatment for obstructive sleep apnea: two randomized trials found no improvement in apnea measures but did observe lethargy and weight gain, which may be unfavorable for the condition. Loud snoring, witnessed breathing pauses, morning headache, or hazardous daytime sleepiness warrants sleep-breathing assessment. Stronger sedation must not mask the problem, and established positive-airway-pressure treatment should not be stopped without clinical direction.

Interactions, serotonin toxicity, cardiac rhythm, and hypotension

Mirtazapine must not be used with a monoamine oxidase inhibitor or crossed over during the specified 14-day washout intervals. Linezolid and intravenous methylene blue can create similarly high-risk situations. Combining it with triptans, tramadol, fentanyl, lithium, buspirone, amphetamines, St. John's wort, or other serotonergic medicines increases serotonin-syndrome risk. A combination of agitation or altered awareness, sweating and fever, unstable heart rate or blood pressure, diarrhea, and tremor, myoclonus, rigidity, or hyperreflexia requires stopping self-escalation and obtaining urgent assessment.

Mirtazapine concentration has a positive relationship with QT prolongation. Postmarketing QT prolongation, torsade de pointes, ventricular tachycardia, and sudden death have been reported, most often with overdose or additional risk factors. Known cardiac disease, a family history of long QT, electrolyte abnormalities, or concurrent QT-prolonging drugs deserve focused review. Orthostatic hypotension may also occur, with greater concern in dehydration, hypovolemia, cardiovascular or cerebrovascular disease, and antihypertensive treatment. Syncope, chest pain, or sustained palpitations needs prompt care. Concurrent warfarin use may require clinically directed INR monitoring.

Mood warnings, hematologic and skin emergencies, and special populations

Antidepressants carry a warning about increased suicidal thoughts and behaviors in children, adolescents, and young adults, especially early in treatment and around dose changes. Sudden worsening depression, agitation, impulsivity, self-harm thoughts, or unusual behavior calls for rapid contact with the care team; imminent danger requires emergency help. Screening for bipolar disorder is important because mania or hypomania can be precipitated. Mirtazapine is not approved for pediatric patients, and adult off-label insomnia practice should not be extrapolated to children.

Rare agranulocytosis can present with fever, sore throat, stomatitis, or recurrent infection and warrants prompt medical assessment and a blood count. A severe DRESS reaction can combine rash, fever, facial swelling, lymph-node enlargement, or liver, kidney, lung, or cardiac involvement and requires immediate care. Eye pain, abrupt vision change, or colored halos may signal angle-closure glaucoma. Hyponatremia can cause headache, poor concentration or memory, confusion, weakness, and unsteady gait, progressing to seizure or coma. Pregnancy, lactation, seizure disorder, and renal or hepatic impairment require individualized assessment rather than abrupt self-discontinuation or substitution.

Discontinuation, overdose response, and continuing reassessment

Abrupt cessation or rapid dose reduction can cause dizziness, abnormal dreams, sensory disturbance or electric-shock sensations, agitation, anxiety, fatigue, confusion, headache, tremor, nausea, vomiting, and sweating. After regular use, a taper is generally planned with the prescriber. Mirtazapine is not a controlled substance, but it must not be shared or casually mixed with alcohol and sedatives. Overdose can cause disorientation, profound drowsiness, impaired memory, tachycardia, QT prolongation, and torsade de pointes; mixed overdoses can be fatal and there is no specific antidote. Suspected overdose requires immediate emergency or poison-center contact, not waiting for sleep to wear off or inducing vomiting.

During continued treatment, a brief record of insomnia severity, wake after sleep onset, total sleep, next-day function, weight and appetite, mood, falls, and infection symptoms can support review at the end of a short trial and thereafter. The goal is meaningful nighttime and daytime improvement, not sedation alone. Store the exact product as labeled, at room temperature, protected from light, tightly closed, and inaccessible to children; do not use tablets of uncertain origin or the wrong formulation. Imminent self-harm, seizure, severe rash or infection, fainting with palpitations, serotonin-syndrome features, or overdose marks an emergency boundary.